» Articles » PMID: 38481254

Patient's and Healthcare Provider's Experiences with Opioid Maintenance Treatment (OMT): a Qualitative Evidence Synthesis

Overview
Publisher Biomed Central
Specialty Health Services
Date 2024 Mar 14
PMID 38481254
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Opioid Maintenance Treatment (OMT) is the gold standard for people with opioid dependence. However, drop-out rates are high, and many patients do not reach desired outcomes. Understanding patients' and healthcare providers' experiences with the treatment can provide valuable information to improve the quality of OMT and to increase acceptability and accessibility of services. The aim of this systematic review is to explore and synthesise the experiences of OMT among persons with opioid dependence and health care providers, to inform policy makers and practitioners on how to improve OMT outcomes.

Methods: We conducted a qualitative evidence synthesis. We systematically searched in electronic databases (CINAHL, Embase, MEDLINE, and nordic databases) and searched for grey literature. As we identified many studies that met our inclusion criteria, we purposively sampled a manageable number of studies to include in this review. Two researchers independently extracted and coded data from the included studies and used the Andersen's healthcare utilization model to organize and develop codes. We assessed the methodological limitations of the studies, and our confidence in the findings using GRADE CERQual.

Results: We retrieved 56 relevant studies and purposively sampled 24 qualitative studies of patients' and healthcare providers' experiences with OMT. Our analyses resulted in six main themes: (1) External stigma prevents engagement and retention in treatment, (2) Being identified as in OMT contributed to an increased experience of stigma (3) Inadequate knowledge and expertise among healthcare providers affected patients' treatment experiences, (4) Quality of communication between personnel and patients impacts patients' engagement with treatment and treatment outcomes, (5) Patients wanted help with many aspects of their lives not just medication, and (6) Balancing positive expectations of OMT with treatment stigma. We found that stigma was an overarching theme across these themes.

Conclusion: Our findings suggest that OMT could be more beneficial for patients if treatment programs prioritize efforts to diminish societal and OMT provider stigma and find strategies to better address patient needs. Initiatives should focus on improving treatment knowledge among providers, encouraging the use of client perspectives, considering the context of family members, and establishing a more holistic and flexible treatment environment.

Citing Articles

Male patients' preferences for opioid use treatment programs.

Amini-Rarani M, Moeeni M, Ponnet K BMC Psychiatry. 2023; 23(1):440.

PMID: 37328768 PMC: 10273501. DOI: 10.1186/s12888-023-04939-x.

References
1.
Mehta N, Clement S, Marcus E, Stona A, Bezborodovs N, Evans-Lacko S . Evidence for effective interventions to reduce mental health-related stigma and discrimination in the medium and long term: systematic review. Br J Psychiatry. 2015; 207(5):377-84. PMC: 4629070. DOI: 10.1192/bjp.bp.114.151944. View

2.
Sohler N, Weiss L, Egan J, Lopez C, Favaro J, Cordero R . Consumer attitudes about opioid addiction treatment: a focus group study in New York City. J Opioid Manag. 2013; 9(2):111-9. PMC: 4012752. DOI: 10.5055/jom.2013.0152. View

3.
Munthe-Kaas H, Bohren M, Glenton C, Lewin S, Noyes J, Tuncalp O . Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 3: how to assess methodological limitations. Implement Sci. 2018; 13(Suppl 1):9. PMC: 5791044. DOI: 10.1186/s13012-017-0690-9. View

4.
Bishop B, Gilmour J, Deering D . Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder. Int J Ment Health Nurs. 2018; 28(1):226-236. DOI: 10.1111/inm.12523. View

5.
Richert T, Johnson B . Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. 2015; 12:1. PMC: 4337060. DOI: 10.1186/s12954-015-0037-2. View